← Back to Search

Stress and Communication Skills Training for Cancer

N/A
Waitlist Available
Led By Kelly Trevino, PhD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of poor prognosis advanced cancer defined as: (1) locally advanced or metastatic cancer (i.e., thoracic, gynecological, genitourinary cancer, pancreatic or lymphoma) or (2) disease progression following at least first line treatment
Must not have
Receiving hospice at the time of enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test an intervention to help manage difficult emotions and communicate about the patient's illness. The intervention is designed to be culturally sensitive and reduce burden to patients, caregivers, and healthcare institutions.

Who is the study for?
This trial is for Latino/a patients with advanced cancer and their caregivers, who are fluent in English or Spanish, reside in New York, and can communicate by phone. Patients must have discussed prognosis with their oncologist and not be receiving hospice care. Caregivers need to provide support without pay and have experience working with advanced cancer patients.
What is being tested?
The study tests a stress management and communication skills intervention tailored for Latinx individuals versus a non-tailored version. Participants will attend weekly 45-minute sessions designed to improve emotional handling, quality of life, understanding of illness, and treatment preferences discussions.
What are the potential side effects?
Since this is a psychosocial intervention involving counseling sessions rather than medication or medical procedures, traditional side effects are not expected. However, discussing sensitive topics may evoke emotional discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I'm sorry, but it seems like you didn't provide any criterion for me to rewrite. Could you please provide the criterion you would like me to summarize?
Select...
My advanced cancer has a poor prognosis and has either spread or not responded to first treatment.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently in hospice care.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: PatientsExperimental Treatment1 Intervention
Latino/a advanced cancer patients
Group II: CaregiversExperimental Treatment1 Intervention
Caregivers of Latino/a advanced cancer patients

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,979 Previous Clinical Trials
600,033 Total Patients Enrolled
157 Trials studying Lymphoma
9,274 Patients Enrolled for Lymphoma
Weill Medical College of Cornell UniversityOTHER
1,092 Previous Clinical Trials
1,154,741 Total Patients Enrolled
40 Trials studying Lymphoma
21,431 Patients Enrolled for Lymphoma
Kelly Trevino, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
81 Total Patients Enrolled

Media Library

Weekly 45 minute Sessions Clinical Trial Eligibility Overview. Trial Name: NCT03794635 — N/A
Lymphoma Research Study Groups: Patients, Caregivers
Lymphoma Clinical Trial 2023: Weekly 45 minute Sessions Highlights & Side Effects. Trial Name: NCT03794635 — N/A
Weekly 45 minute Sessions 2023 Treatment Timeline for Medical Study. Trial Name: NCT03794635 — N/A
~6 spots leftby Dec 2025